Identifying Complex High-Risk Individuals (HRI-C) for Early Detection of Occult Pancreatic Cancers Using Risk Models and Biomarkers.
DOI:
https://doi.org/10.69734/525x3s54Keywords:
SEER Program, Early Detection of Cancer, Early Detection, Genetic Testing, Computer-Assisted Numerical Analysis, Multifactorial Inheritance, Pancreatic Neoplasms, High-riskAbstract
Early detection and diagnosis of pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) offers the best option for effective treatment and prolonged survival. Image-based screening programs are useful in early detection of pancreatic cancers in high-risk individuals (HRI) defined by strong family history and/or pathogenic variants (PV) in hereditary cancer syndrome (HCS) genes associated with an increased risk for PDAC development. However, this only applies in about 10% of people who eventually develop pancreatic cancer. An additional 15% of PDACs are associated with a pancreatic cystic neoplasms. Thus, the majority (~75%) of patients diagnosed with PDAC are not candidates for surveillance under an existing framework. Based on growing evidence we believe that early detection is also possible in what we call Complex High-Risk Individuals (HRI-C) through frequent, time-limited image-based screening. These HRI-C are identified by combining multiple clinical and genetic risk factors alongside early markers of pancreatic cancer (e.g. family history, past medical history, social history, and multiple genetic factors in individuals with worrisome individual or combinations of biomarkers of occult pancreatic cancer in older individuals (>50 years) such as new onset diabetes (NOD), new idiopathic acute or chronic pancreatitis, maldigestion with exocrine pancreatic insufficiency (EPI), abnormal liver injury test (especially biliary), unexplained weight loss and typical cancer-associated pain patterns). Here we propose a potentially cost-effective clinical decision pathway aimed at improving early detection, diagnosis and outcomes of this large group of individuals at risk for developing PDAC.
References
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186-98 D.O.I: 10.1093/ije/dyu240. PMID: 25502106
Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol. 2022;40(28):3257-66 D.O.I: 10.1200/JCO.22.00298. PMID: 35704792
Archibugi L, Casciani F, Carrara S, Secchettin E, Falconi M, Capurso G, et al. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high-risk individuals. Fam Cancer. 2024;23(3):373-82 D.O.I: 10.1007/s10689-024-00366-3. PMID: 38493228
Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020;18(4):380-91 D.O.I: 10.6004/jnccn.2020.0017. PMID: 32259785
Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):824-48 e22 D.O.I: 10.1053/j.gastro.2015.01.014. PMID: 25805376
Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490-500 e2 D.O.I: 10.1053/j.gastro.2018.04.025. PMID: 29723506
Sharma A, Kandlakunta H, Nagpal SJS, Feng Z, Hoos W, Petersen GM, et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018;155(3):730-9 e3 D.O.I: 10.1053/j.gastro.2018.05.023. PMID: 29775599
Khan S, Safarudin RF, Kupec JT. Validation of the ENDPAC model: Identifying new-onset diabetics at risk of pancreatic cancer. Pancreatology. 2021;21(3):550-5 D.O.I: 10.1016/j.pan.2021.02.001. PMID: 33583686
Dbouk M, Abe T, Koi C, Ando Y, Saba H, Abou Diwan E, et al. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges. Clin Cancer Res. 2023;29(20):4178-85 D.O.I: 10.1158/1078-0432.CCR-23-0655. PMID: 37566230
Whitcomb DC, Oranburg TD, Vallente R, Brand RE. SMART Medical Review: CA 19-9 and pancreatic ductal adenocarcinoma (PDAC).: CA 19-9 and Pancreatic Cancer. SMART-MD JPM. 2024;1(1):14-27 D.O.I: https://doi.org/10.69734/psc3br75.
Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer Screening. Gastroenterology. 2020;158(2):418-32 D.O.I: 10.1053/j.gastro.2019.06.043. PMID: 31394083
Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023;20(9):902-14 D.O.I: 10.1016/j.jacr.2023.04.002. PMID: 37150275
Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19(2):182-6 D.O.I: 10.1111/j.1440-1746.2004.03219.x. PMID: 14731128
Konings I, Canto MI, Almario JA, Harinck F, Saxena P, Lucas AL, et al. Surveillance for pancreatic cancer in high-risk individuals. BJS Open. 2019;3(5):656-65 D.O.I: 10.1002/bjs5.50180. PMID: 31592073
Baydogan S, Mohindroo C, Hasanov M, Montiel MF, Quesada P, Cazacu IM, et al. New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study. Endosc Ultrasound. 2024;13(2):83-8 D.O.I: 10.1097/eus.0000000000000057. PMID: 38947744
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17 D.O.I: 10.1136/gutjnl-2019-319352. PMID: 31672839
Sawhney MS, Calderwood AH, Thosani NC, Rebbeck TR, Wani S, Canto MI, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022;95(5):817-26 D.O.I: 10.1016/j.gie.2021.12.001. PMID: 35183358
Tempero MA. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019;17(5.5):603-5 D.O.I: 10.6004/jnccn.2019.5007. PMID: 31117041
Porter N, Laheru D, Lau B, He J, Zheng L, Narang A, et al. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. J Natl Cancer Inst. 2022;114(12):1681-8 D.O.I: 10.1093/jnci/djac167. PMID: 36029239
Molina-Montes E, Gomez-Rubio P, Marquez M, Rava M, Lohr M, Michalski CW, et al. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Int J Epidemiol. 2018;47(2):473-83 D.O.I: 10.1093/ije/dyx269. PMID: 29329392
Gonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, et al. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointest Endosc. 2022;95(4):723-32 e7 D.O.I: 10.1016/j.gie.2021.10.025. PMID: 34736932
Solea SF, Brisc MC, Oraseanu A, Venter FC, Brisc CM, Solea RM, et al. Revolutionizing the Pancreatic Tumor Diagnosis: Emerging Trends in Imaging Technologies: A Systematic Review. Medicina (Kaunas). 2024;60(5) D.O.I: 10.3390/medicina60050695. PMID: 38792878
Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, Hijioka S, Jang JY, Lennon AM, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024;24(2):255-70 D.O.I: 10.1016/j.pan.2023.12.009. PMID: 38182527
Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738-53 D.O.I: 10.1016/j.pan.2017.07.007. PMID: 28735806
Hamada T, Oyama H, Tange S, Hakuta R, Ishigaki K, Kanai S, et al. The Revised Kyoto Criteria and Risk of Malignancy Among Patients With Intraductal Papillary Mucinous Neoplasms. Clin Gastroenterol Hepatol. 2024;22(12):2413-23 e18 D.O.I: 10.1016/j.cgh.2024.05.043. PMID: 38880125
Nikiforova MN, Wald AI, Spagnolo DM, Melan MA, Grupillo M, Lai YT, et al. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising from Pancreatic Cysts. Ann Surg. 2023 D.O.I: 10.1097/SLA.0000000000005904. PMID: 37212422
Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genetics. 1996;14(2):141-5 D.O.I. PMID: 8841182
Shelton CA, Grubs RE, Umapathy C, Yadav D, Whitcomb DC. Impact of hereditary pancreatitis on patients and their families. J Genet Couns. 2020 D.O.I: 10.1002/jgc4.1221. PMID: 32026589
Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. Journal of the American Medical Association. 2001;286(2):169-70 D.O.I. PMID: 11448279
Greenhalf W, Levy P, Gress T, Rebours V, Brand RE, Pandol S, et al. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology. 2020;20(5):910-8 D.O.I: 10.1016/j.pan.2020.05.011. PMID: 32624419
Tajbakhsh J, Debernardi S, Blyuss O, Bai J, Weng R, Lo S, et al. A CLIA/CAP Compliant Noninvasive Laboratory Developed Test for Early Detection of Pancreatic Ductal Adenocarcinoma. J Mol Diagn. 2024 D.O.I: 10.1016/j.jmoldx.2024.10.001. PMID: 39521243
Brezgyte G, Shah V, Jach D, Crnogorac-Jurcevic T. Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer-A Comprehensive Review. Cancers (Basel). 2021;13(11) D.O.I: 10.3390/cancers13112722. PMID: 34072842
Haab B, Qian L, Staal B, Jain M, Fahrmann J, Worthington C, et al. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 2024;604:217245 D.O.I: 10.1016/j.canlet.2024.217245. PMID: 39276915
Reyaz I, Khan B, James N, Azhar H, Rehman A, Younas MW, et al. Emerging Horizons in the Diagnosis of Pancreatic Cancer: The Role of Circulating microRNAs as Early Detection Biomarkers for Pancreatic Ductal Adenocarcinoma. Cureus. 2024;16(1):e53023 D.O.I: 10.7759/cureus.53023. PMID: 38410292
Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett. 2017;393:86-93 D.O.I: 10.1016/j.canlet.2017.02.019. PMID: 28232049
Zhao Y, Tang J, Jiang K, Liu SY, Aicher A, Heeschen C. Liquid biopsy in pancreatic cancer - Current perspective and future outlook. Biochim Biophys Acta Rev Cancer. 2023;1878(3):188868 D.O.I: 10.1016/j.bbcan.2023.188868. PMID: 36842769
Binkowski B, Klamer Z, Gao C, Staal B, Repesh A, Tran HL, et al. Multiplexed Glycan Immunofluorescence Identification of Pancreatic Cancer Cell Subpopulations in Both Tumor and Blood Samples. bioRxiv. 2024 D.O.I: 10.1101/2024.08.22.609143. PMID: 39229066
Perry LM, Bateni SB, Bold RJ, Hoch JS. Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers? Journal of the American College of Surgeons. 2021;233(1):90-8 D.O.I: 10.1016/j.jamcollsurg.2021.02.014. PMID: 33766724
Peters MLB, Eckel A, Seguin CL, Davidi B, Howard DH, Knudsen AB, et al. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. JCO Oncol Pract. 2024;20(2):278-90 D.O.I: 10.1200/OP.23.00495. PMID: 38086003
Wang L, Levinson R, Mezzacappa C, Katona BW. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Fam Cancer. 2024;23(3):351-60 D.O.I: 10.1007/s10689-024-00392-1. PMID: 38795221
Ibrahim IS, Vasen HFA, Wasser M, Feshtali S, Bonsing BA, Morreau H, et al. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort. United European gastroenterology journal. 2023;11(2):163-70 D.O.I: 10.1002/ueg2.12360. PMID: 36785917
Placido D, Yuan B, Hjaltelin JX, Zheng C, Haue AD, Chmura PJ, et al. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Nat Med. 2023;29(5):1113-22 D.O.I: 10.1038/s41591-023-02332-5. PMID: 37156936
Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95-101 D.O.I: 10.1053/j.gastro.2007.10.040. PMID: 18061176
Shah I, Wadhwa V, Bilal M, Germansky KA, Sawhney MS, Pancreas Cancer Screening Study G. Prospective Assessment for Prediabetes and New-Onset Diabetes in High-Risk Individuals Undergoing Pancreatic Cancer Screening. Gastroenterology. 2021;161(5):1689-91 e1 D.O.I: 10.1053/j.gastro.2021.06.055. PMID: 34175285
Boursi B, Finkelman B, Giantonio BJ, Haynes K, Rustgi AK, Rhim AD, et al. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology. 2017;152(4):840-50 e3 D.O.I: 10.1053/j.gastro.2016.11.046. PMID: 27923728
Kowada A. Cost-effectiveness of Abdominal Ultrasound Versus Magnetic Resonance Imaging for Pancreatic Cancer Screening in Familial High-Risk Individuals in Japan. Pancreas. 2020;49(8):1052-6 D.O.I: 10.1097/MPA.0000000000001614. PMID: 32769852
Schwartz NRM, Matrisian LM, Shrader EE, Feng Z, Chari S, Roth JA. Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. J Natl Compr Canc Netw. 2021;20(5):451-9 D.O.I: 10.6004/jnccn.2020.7798. PMID: 34153945
Grigorescu RR, Husar-Sburlan IA, Gheorghe C. Pancreatic Cancer: A Review of Risk Factors. Life (Basel). 2024;14(8) D.O.I: 10.3390/life14080980. PMID: 39202722
Jeong SH, Hurh K, Park EC, Leigh JH, Kim SH, Jang SI. Risk of Pancreatic Cancer After Acute Pancreatitis: A Retrospective Analysis of the Korean National Sample Cohort. J Korean Med Sci. 2024;39(4):e21 D.O.I: 10.3346/jkms.2024.39.e21. PMID: 38288535
Sadr-Azodi O, Oskarsson V, Discacciati A, Videhult P, Askling J, Ekbom A. Pancreatic Cancer Following Acute Pancreatitis: A Population-based Matched Cohort Study. Am J Gastroenterol. 2018;113(11):1711-9 D.O.I: 10.1038/s41395-018-0255-9. PMID: 30315287
Kirkegard J, Cronin-Fenton D, Heide-Jorgensen U, Mortensen FV. Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark. Gastroenterology. 2018;154(6):1729-36 D.O.I: 10.1053/j.gastro.2018.02.011. PMID: 29432727
Munigala S, Kanwal F, Xian H, Scherrer JF, Agarwal B. Increased risk of pancreatic adenocarcinoma after acute pancreatitis. Clin Gastroenterol Hepatol. 2014;12(7):1143-50 e1 D.O.I: 10.1016/j.cgh.2013.12.033. PMID: 24440214
Chandana SR, Woods LM, Maxwell F, Gandolfo R, Bekaii-Saab T. Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. Eur J Cancer. 2024;198:113471 D.O.I: 10.1016/j.ejca.2023.113471. PMID: 38154392
Munigala S, Almaskeen S, Subramaniam DS, Bandi S, Bowe B, Xian H, et al. Acute Pancreatitis Recurrences Augment Long-Term Pancreatic Cancer Risk. Am J Gastroenterol. 2023;118(4):727-37 D.O.I: 10.14309/ajg.0000000000002081. PMID: 36473072
Li Z, Jin L, Xia L, Li X, Guan Y, He H. Body mass index, C-reactive protein, and pancreatic cancer: A Mendelian randomization analysis to investigate causal pathways. Front Oncol. 2023;13:1042567 D.O.I: 10.3389/fonc.2023.1042567. PMID: 36816931
Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, et al. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016;16:218-24 D.O.I: 10.1016/j.pan.2016.02.001. PMID: 26924663
Cho J, Scragg R, Petrov MS. Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results From a Nationwide Cancer Registry. Diabetes Care. 2020 D.O.I: 10.2337/dc20-0207. PMID: 32616613
Cook ME, Bruun NH, Davidsen L, Drewes AM, Olesen SS. Multistate Model of the Natural History of Inflammatory Pancreatic Diseases: A Nationwide Population-based Cohort Study. Gastroenterology. 2023;165(6):1547-57 e4 D.O.I: 10.1053/j.gastro.2023.08.042. PMID: 37659669
Singhi AD, Nikiforova MN, Chennat J, Papachristou GI, Khalid A, Rabinovitz M, et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut. 2020;69(1):52-61 D.O.I: 10.1136/gutjnl-2018-317817. PMID: 30971436
Boursi B, Finkelman B, Giantonio BJ, Haynes K, Rustgi AK, Rhim AD, et al. A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. Eur J Gastroenterol Hepatol. 2022;34(1):33-8 D.O.I: 10.1097/MEG.0000000000002052. PMID: 33470698
Sharma S, Tapper WJ, Collins A, Hamady ZZR. Predicting Pancreatic Cancer in the UK Biobank Cohort Using Polygenic Risk Scores and Diabetes Mellitus. Gastroenterology. 2022;162(6):1665-74 e2 D.O.I: 10.1053/j.gastro.2022.01.016. PMID: 35065983
Bogumil D, Conti DV, Sheng X, Xia L, Shu XO, Pandol SJ, et al. Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2686-92 D.O.I: 10.1158/1055-9965.EPI-20-0963. PMID: 32958499
Cao K, Xia Y, Yao J, Han X, Lambert L, Zhang T, et al. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Nat Med. 2023;29(12):3033-43 D.O.I: 10.1038/s41591-023-02640-w. PMID: 37985692
Downloads
Published
Versions
- 2024-12-26 (2)
- 2024-12-23 (1)
Issue
Section
License
Copyright (c) 2024 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information